Gelonghui, November 25 - JAKOS-B (01167.HK) announced that the first patient has been administered the pan-KRAS inhibitor JAB-23E73, which was developed in-house, in the I/IIa clinical trial in china. KRAS is widely present in various tumor mutations, with approximately 23%-25% of cancer patients carrying KRAS mutations. Globally, about 2.7 million newly diagnosed cancer patients with KRAS-related mutations are expected to benefit from pan-KRAS inhibitors each year.

JAB-23E73 can simultaneously inhibit the active and inactive states of KRAS, and has no significant inhibition on HRAS and NRAS. As an oral KRAS inhibitor, JAB-23E73 has shown good pharmacokinetic characteristics in preclinical data.